EU Review Gets Under Way For Curative Vision Loss Gene Therapy
US Filing Of GenSight’s Lumevoq Will Come Later, In H2 2021
GenSight Biologics believes Lumevoq could become the first curative treatment for Leber hereditary optic neuropathy.
GenSight Biologics believes Lumevoq could become the first curative treatment for Leber hereditary optic neuropathy.